Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Executive Summary

Only 8% of original ANDAs submitted in the user fee program’s third year were approved on the first cycle, compared with 72% that received a complete response letter.

Advertisement

Related Content

ANDA Approval Times Get Optimistic Estimate In Budget Request
Generic Priority Review Expanded In Senate User Fee Bill
ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals
US FDA Might Face Funding Penalty For Missing User Fee Goals
Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?
Bill To Speed ANDA Approvals Gets Cool Reception From Industry, US FDA
Generic Application Quality Showing Signs Of Improvement
ANDA Submission Wave Continues; Is A Crest Near?
Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Topics

Advertisement
UsernamePublicRestriction

Register

PS119392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel